NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis $6.45 +0.22 (+3.50%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$6.54 +0.09 (+1.40%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dermata Therapeutics Stock (NASDAQ:DRMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dermata Therapeutics alerts:Sign Up Key Stats Today's Range$6.01▼$6.8850-Day Range$0.59▼$6.4552-Week Range$5.74▼$37.90Volume97,087 shsAverage Volume189,143 shsMarket Capitalization$41.15 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company Overview Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Read More Dermata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreDRMA MarketRank™: Dermata Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingDermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDermata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Dermata Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 10.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dermata Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.01% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently increased by 49.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.01% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently increased by 49.85%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News Sentiment-1.00 News SentimentDermata Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dermata Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for DRMA on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.50% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.67% of the stock of Dermata Therapeutics is held by institutions.Read more about Dermata Therapeutics' insider trading history. Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DRMA Stock News HeadlinesDermata Therapeutics, Inc. (DRMA) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comDermata Therapeutics Inc News (DRMA) - Investing.comJuly 10, 2025 | investing.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 2 at 2:00 AM | Crypto 101 Media (Ad)Dermata Therapeutics: Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for HyperhidrosisJuly 8, 2025 | finanznachrichten.deDermata’s XYNGARI trial hits statistically significant difference at 4 weeksApril 17, 2025 | markets.businessinsider.comDermata Therapeutics files to sell 10.01M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comDermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksApril 15, 2025 | finanznachrichten.deDermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksApril 15, 2025 | finance.yahoo.comSee More Headlines DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed this year? Dermata Therapeutics' stock was trading at $1.35 at the start of the year. Since then, DRMA stock has increased by 377.8% and is now trading at $6.45. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.45). When did Dermata Therapeutics' stock split? Dermata Therapeutics's stock reverse split before market open on Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $18 million in an IPO on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share. How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dermata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings5/14/2025Today8/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRMA CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for Dermata Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside-53.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($16.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-270.81% Return on Assets-179.96% Debt Debt-to-Equity RatioN/A Current Ratio3.70 Quick Ratio3.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book10.40Miscellaneous Outstanding Shares6,380,000Free Float5,198,000Market Cap$41.15 million OptionableNot Optionable Beta0.56 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:DRMA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.